Oncology Peer Review On-The-Go: Is Next-Generation Sequencing a Right for Patients with GI Cancers?
The newest episode of “Oncology Peer Review On-The-Go” features 2 competing opinions on next-generation sequencing for the treatment of gastrointestinal cancers.
In the latest episode of “Oncology Peer Review On-The-Go,” CancerNetwork examines a Q&A piece in the August issue of the journal ONCOLOGY discussing next-generation sequencing for gastrointestinal (GI) cancers. The article is titled “Ushering in the Era of Precision Medicine” and it focuses on a conversation with Tanios Bekaii-Saab, MD, of the Mayo Clinic in Phoenix, Arizona.
For a responding perspective, CancerNetwork spoke with Howard Hochster, MD, of the Rutgers Cancer Institute of New Jersey. Dr. Hochster, who is also co-editor in chief of ONCOLOGY, discussed his feelings regarding next-generation sequencing, and suggests alternative ways to treat patients with GI cancers.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
!["[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F8987adec8367653dbaf8fc0f82c7dbfcb914281e-500x404.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy,\" according to the study authors.")
